Concepedia

ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update

Sofía Ramiro, Elena Nikiphorou, Alexandre Sepriano, Augusta Ortolan, Casper Webers, Xenofon Baraliakos, Robert Landewé, Filip Van den Bosch, B. Boteva, Ann Bremander,

Annals of the Rheumatic Diseases · 2022 · 929 citations · 117 references

DOIFull text

Open access

Concepts

References

117

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Stephen B. Hanauer, Brian G. Feagan, Gary R. Lichtenstein et al. · The Lancet · 2002 · 4.2K citations

, , +12

The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection

Martín Rudwaleit, Désirée van der Heijde, R. B. M. Landewé et al. · Annals of the Rheumatic Diseases · 2009 · 3.6K citations · Full text

, , +11

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis

Steven R. Ytterberg, Deepak L. Bhatt, Ted R. Mikuls et al. · New England Journal of Medicine · 2022 · 1.7K citations · Full text

, , +15

The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis

Joachim Sieper, Martín Rudwaleit, Xenofon Baraliakos et al. · Annals of the Rheumatic Diseases · 2009 · 1.6K citations

, , +14

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

Wolfgang Hueber, Bruce E. Sands, Steve Lewitzky et al. · Gut · 2012 · 1.5K citations · Full text

, , +15